High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy

Area of Science:

• Hematology
• Oncology
• Stem Cell Transplantation

Background:

• Autologous stem cell transplant (SCT) is a standard treatment for multiple myeloma (MM), improving patient survival.
• A significant proportion of newly diagnosed MM patients are primary refractory, failing to respond to initial therapies.
• The impact of initial treatment response on SCT success in primary refractory MM is not well understood.

Purpose of the Study:

• To evaluate the efficacy of SCT in patients with primary refractory multiple myeloma.
• To compare SCT outcomes in primary refractory MM versus chemosensitive MM.
• To determine if an initial response to therapy is essential for successful SCT.

Main Methods:

• Retrospective analysis of 50 patients with primary refractory MM undergoing SCT.
• Comparison with 101 patients with chemosensitive MM who received SCT.
• Assessment of response rates (≥50% M-protein reduction) and complete remission (CR) post-SCT.
• Evaluation of 1-year progression-free survival (PFS) from transplant.

Main Results:

• High response rates to SCT were observed in both groups: 92% in refractory and 99% in chemosensitive MM.
• Complete remission rates were 20% for refractory and 35% for chemosensitive MM (P=0.06).
• One-year PFS was 70% for refractory MM and 83% for chemosensitive MM (P=0.65).

Conclusions:

• Initial lack of response to induction therapy does not prevent a favorable response to autologous SCT in MM.
• Patients with primary refractory MM should be considered for early SCT.
• SCT remains a viable and recommended treatment option for eligible patients with primary refractory MM.